Savient's Krystexxa to undergo NICE test
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, is to appraise Savient's gout treatment Krystexxa (pegloticase), according to a draft appraisal scope put out for consultation.